Sıra | DOSYA ADI | Format | Bağlantı |
---|---|---|---|
01. | Pediatrics Patient Response Steroids | ppt | Sunumu İndir |
Transkript
Minimizing Growth Suppression in Children with Steroid-sensitive Nephrotic SyndromeAlex Constantinescu, MDDirector, Pediatric NephrologyJoe DiMaggio Children’s HospitalHollywood, Florida
Outline• Define steroid-sensitive nephrotic syndrome• Disease course – relapse pattern• Side effects of steroids• Growth suppression data• Strategies to prevent growth-suppression
Definition• “Nephrotic Syndrome = clinical entity having multiple causes, characterized by high glomerular membrane permeability, manifested by massive proteinuria and lipiduria, …in the absence of depressed GFR.” (G. Schreiner, 1963)• Upr excretion rates are usually >40 mg/m2/hr in children, or >1 g protein/g creatinine (random sample)
Childhood Nephrotic Syndrome (NS)• Most common cause: minimal change disease (MCD)• First line of therapy: corticosteroids – daily followed by alternate day• Many protocols ISKDC – 1978, 1981
Types of Nephrotic Syndrome• Based on steroid sensitivity:– steroid-responsive (protein-free)• Infrequent relapsers (<2 in a year)• Frequent relapsers (2 in 6 months, or >3 in a year)• Steroid-dependent (within 1 month after steroids stopped or while on alternate day therapy) – steroid-resistant (no response after 4-6 weeks)
Systems Affected by Steroid Therapy• Gastro-intestinal (gastritis)• Cardio-vascular (hypertension)• Hematological (leukocytosis, immunosuppression)• Neuro-psychological (psychosis, depression)• Bone metabolism (osteoporosis)• Skin and Eye (striae, cataracts)• Glucose metabolism (diabetes, cushingoid body habitus)• Growth – suppression, leading to short stature
Steroid-induced Growth Suppression - MechanismsHypothalamusPituitaryLiverGrowth plateConnective tissueAdrenal glandGHRH Somatostatin+ -Pulsatile GH secretion+IGF-1+ GH receptorexpression andbinding; IGF-1 activitySteroids+----
Impact of Short Stature• Body image• Psychosocial adaptation• Bone metabolism• Pubertal development
• Single center - Robert Wood Johnson Medical School, New Brunswick, NJ• We sought to identify:– Degree of growth suppression caused by steroid therapy in children with NS, presumed to have MCD– Moment of “maximum impact”– Frequency of this adverse effect – Is this long-lasting?• Patients with focal segmental sclerosis on biopsy, as well as those with other steroid-resistant forms of NS were excluded• Data entered in GrowTrack v 1.0.6 Software (Genentech, Inc.)• Standard deviation scores (SDS) for Ht (HtSDS) and GR (GRSDS), were calculated and compared with normal values for age and genderGrowth in Children with Nephrotic SyndromeCederbaum N, Constantinescu A. J Investigative Medicine 50:187, 2002.
Results• 69 children with complete growth data• 44 boys, 25 girls, M:F=1.8:1• Age range 1-17.8 years• Younger than 6 yrs of age 75.4% • Older than 6 yrs of age 24.6%
Ht SDS in Children with Nephrotic Syndrome-4-3-2-101234TimeHt SDS3m 6m 1y 2y 3y 4y 5y 6y 7y 8y 9y 10y 11y-1.8 SD
HtSDS in Children with Nephrotic Syndrome-3-2-10123456HtSDSHtSDS in M<6y (n=31)HtSDS in F<6y (n=21)HtSDS in M>6y (n=13)HtSDS in F>6y (n=4)3 mos 6 mos 12 mos
Growth Rate SDS in Children with Nephrotic Syndrome-8-6-4-2024681012TimeGrowth Rate SDS3m 6m 1y 2y 3y 4y 5y 6y 7y 8y 9y 10y 11y 12y
Growth Velocity Rate (GVR) in Children with NS 0.05.010.015.020.0p=0.0293 m 6 m 12 mGVR for 3-6-12 mo.0.05.010.015.020.03 m 6 m 12 mMFM F M FGVR - M vs. F <6 yrs.p=0.0190.05.010.015.020.03 m 6 m 12 mMFMFMGVR - M vs. F >6 yrs.
Long-term Linear Growth in Children with SD or FR Nephrotic SyndromeEmma F, et al. Pediatr Nephrol 18:783-8, 2003• 56 children (37 M, 19 F) followed-up for 10.5±3.1 yrs• SD = 42, FR = 14• Average growth loss was 0.66±0.89 SD• 2 patients fell below -2SD• 23 reached final height with loss of:• 0.92±0.8 HtSDS from the onset of disease (p=0.001)• 0.68±0.7 HtSDS from predicted target height (p=0.001)• Correlated with steroid dose – higher risk if more than 6 months• Growth velocity rate lower in younger children, <4 yrs
So far …• Reviewed the impact of steroids on growth• How can we minimize exposure to steroids?– Lower the frequency of relapse– Lower the initial dose of steroids• Can we tailor the therapy?
Tailor Therapy• Arbeitsgemanschaft für Pädiatrische Nephrologie published in 1998, in Lancet, the finding that 6 weeks of daily steroids + 6 weeks of alternate day steroids appear to reduce the relapse rate – larger cumulative steroid dose• Niaudet and Habib in 1994 introduced cyclosporine in the treatment of NS, as steroid-sparing agent.• No sustained remission, additional side effects• Segregate according to “days to remission” ?
Predictors of Frequent Relapses in NS• Mishra et al. J Trop Pediatr 2013; 59:343-349– 60% relapse (150 – 1 year) – young age and longer time to remission predicts frequent relapsing course • Harambat et al. Pediatr Nephrol 2013; 28:631-638– 70% FR/SD (120 – 6.7 years) – longer time to remission predicts use of steroid-sparing agents• Sureshkumar et al. Pediatr Nephrol 2014; 29:1039–1046– 66% relapse (129 – 1 year) – male, young age, short time to first relapse predicts FR
Distribution Based on Days to Remission02468101214161820No. of Patients1 wk 2 wks 4 wks >4 wksDays to RemissionIR FR+SDConstantinescu et al, Pediatrics 2000; 105:492-495
Disease Course in Patientswith Hematuria0510Nr. patients with hematuriaRelapse pattern vs. Days to remission0-7 >7 IRFR+SDConstantinescu et al, Pediatrics 2000; 105:492-495
Disease Course in Patients without Hematuria0246810121416Nr. Patients without hematuriaRelapse Pattern vs. Days to remission0-7>7IRFR+SDConstantinescu et al, Pediatrics 2000; 105:492-495*Predictsinfrequent relapsing course* p<0.05
MDR-1 Gene Polymorphism• MDR-1 encodes for P-glycoprotein-170, a biological barrier• Up-regulated MDR-1 gene expression correlates with a poor response to steroids• MDR-1 polymorphism studies – in NS, TT genotype associated with a delayed response to steroids and a FR courseWasilewska, A, et al. Pediatr Nephrol 22:44-51, 2007
Our Approach to Minimize Exposure to Steroids• Establish the diagnosis of nephrotic syndrome• Determine if hematuria is present at the onset• Start steroid therapy• Parents call first day urine is protein-free• With hematuria, steroids 6 wks QD + 6 wks QOD• Without hematuria AND response in >1 wk, therapy for 6 wks QD + 6 wks QOD • Without hematuria AND response in <1 wk, therapy only for 4 wks QD + 4 wks QOD• No response in 4 wks - kidney biopsy
Our Data• 2006 – present: 60 children with steroid-sensitive NS• 26 with complete growth records• 34 – either recently diagnosed, incomplete records, or lost to follow-up• Relapse pattern noted (IR, FR/SD)• Initial steroid course (4+4 or 6+6)• Ht SDS at the last visit
Ht SDS - A Function of Relapse Pattern and Steroid DoseHt SDS in Children with NS-1.6-1.4-1.2-1-0.8-0.6-0.4-0.200.20.4Ht SDSIR 4+4 IR 6+6 FR/SD 6+6(pre-SSA)FR/SD 6+6(on SSA, last)SSA = patient receiving steroid-sparing agent (tacrolimus or cyclosporine)* p = 0.039 between IR 4+4 and pre-SSA# p = 0.0000133 between pre-SSA and last visit on SSA¶ p = 0.29 between IR 4+4 and FR/SD 6+6 at last visit on SSA5 11 10*10#,¶
Conclusions• Steroids have growth-suppression potential• Attempts needed to minimize the exposure• Change in daily dose is not recommended • Cumulative dose can be decreased by predicting the infrequent relapsing pattern based on:– response within one week and, – the absence of hematuria.• Prospective studies needed